{"id":22296,"date":"2021-03-26T14:00:21","date_gmt":"2021-03-26T13:00:21","guid":{"rendered":"http:\/\/v3.alumni.test.polimi.it\/?p=22296"},"modified":"2022-11-23T09:58:19","modified_gmt":"2022-11-23T08:58:19","slug":"nuove-terapie-una-spin-off-del-politecnico-per-curare-la-maculopatia","status":"publish","type":"post","link":"https:\/\/v3.alumni.test.polimi.it\/en\/2021\/03\/26\/nuove-terapie-una-spin-off-del-politecnico-per-curare-la-maculopatia\/","title":{"rendered":"New therapies: a spin-off of Politecnico to treat maculopathy"},"content":{"rendered":"

The Exudative maculopathy<\/strong> is a very common eye desease and represents the first cause of loss of sight for people over 50<\/strong>To treat it, until today, it is necessary to have a frequent cycle of injection, an invasive procedure with a high impact on the life of patients, that often abandon their therapy.<\/p>\n\n\n\n

To avoid the premature abandonment of the treatment, a group of researchers of the Department of Chemistry, Materials and Chemical Engineering \"Giulio Natta\" of Politecnico di Milano<\/strong> in collaboration with the Deparment of clinical and biomedical sciences \"Luigi Sacco, ASST Fatebenefratelli-Sacco, Universit\u00e0 degli Studi di Milano, it has developed Mag Shell<\/a>a device that with a singular injection is able to release precise doses of medicine in defined intervals.<\/p>\n\n\n\n

The device was first created in 2015 from the Phd thesis of Marco Ferroni<\/strong>biomedical engineer of Politenico di Milano. In six years, thanks to the support of Polihub <\/strong>that has incubated MgShell<\/a><\/strong>the spin off which has gained a lot of prizes and investments the technology and the business model were developed.<\/p>\n\n\n\n

<\/div>\n\n\n\n
\"\"
Credits: Polihub<\/figcaption><\/figure>\n\n\n\n
<\/div>\n\n\n\n
MAG SHELL: A NEW THERAPEUTIC FRONTIER FOR EXUDATIVE MACULOPATHY<\/strong><\/h5>\n\n\n\n
<\/div>\n\n\n\n

The Mag Shell<\/strong> ocular device is a drug \"container\" that is inserted, with a single injection, into the eye and releases the active ingredient gradually<\/strong>, thus ensuring greater patient adherence to the therapeutic protocol.<\/strong><\/p><\/p>\n\n\n\n

This operation is possible thanks to the conformation of the device itself, which alternates layers of biodegradable materials<\/strong>, consisting of magnesium or its alloys, with drug doses.<\/p> materiali biodegradabili<\/strong>, costituiti da magnesio o da sue leghe, a dosi di farmaco.<\/p>\n\n\n\n

\"Today this means avoiding that 40% of patients who drop out of therapy go blind,<\/strong> it means drastically reducing the social impact that chronic diseases have\" explains Ferroni in an interview.<\/a><\/p><\/p>\n\n\n\n

The advantages of this procedure are many: in addition to the reduction of costs and the impact of current drug treatment<\/strong> on maculopathic patients, hospital staff and on healthcare costs, there are promising possibilities for using MagShell in other areas of pharmaceutical application as well.<\/p><\/p>\n\n\n\n

The device is currently in a preclinical in vitro trial phase and the first animal pilot study will begin soon.<\/p> primo studio pilota su animale<\/strong>.<\/p>\n\n\n\n

Cover Photo: Polihub<\/p>\n\n\n\n

<\/div>\n\n\n\n
\n

MAP is the magazine of the Alumni of Politecnico di Milano\nThe magazine is your compass to navigate everything that is developing and changing in our University.\nBelow you will find a related article <\/b>: if you like what you are seeing, support us <\/a> <\/b>. You will be able to collect your copy for free.<\/p><\/div><\/a>\n\n\n\n